{"gene":"IDUA","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1990,"finding":"IDUA (alpha-L-iduronidase) was chromosomally localized to human chromosome 4p16.3 by in situ hybridization and Southern blot analysis of human-mouse hybrid cell lines, confirming IDUA encodes the lysosomal hydrolase responsible for degrading glycosaminoglycans heparan sulfate and dermatan sulfate.","method":"In situ hybridization, Southern blot analysis of human-mouse somatic cell hybrids, enzyme activity assay","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (in situ hybridization, Southern blot, hybrid cell enzyme activity), replicated finding","pmids":["2220820"],"is_preprint":false},{"year":1992,"finding":"The canine IDUA gene contains 14 exons spanning 13 kb, has a GC-rich promoter with Sp1 binding sites but no TATA box or CAAT motif (housekeeping gene architecture), and the canine MPS I mutation is a G→A transition at the donor splice site of intron 1, causing intron 1 retention in the RNA and a premature termination codon at the exon-intron junction.","method":"Gene cloning, restriction analysis, RT-PCR, primer extension, sequence analysis of genomic DNA","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct sequencing plus RT-PCR confirmation of aberrant RNA product, mutation confirmed by restriction analysis","pmids":["1339393"],"is_preprint":false},{"year":1993,"finding":"Missense mutations Thr366→Pro and Ter→Cys in IDUA permit expression of only trace alpha-L-iduronidase activity; Gly409→Arg permits expression of ~60% normal activity. Nonsense mutation Tyr64→Ter causes very low mRNA levels and exon 2 skipping; Gln310→Ter causes use of a cryptic splice site. Established that specific IDUA mutations have distinct molecular consequences on RNA processing and enzyme activity.","method":"Transfection of mutagenized cDNAs into COS-1 cells, enzyme activity assay, RT-PCR analysis of RNA processing","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct expression of mutagenized cDNAs with enzyme activity measurements, combined with RNA processing analysis","pmids":["8328452"],"is_preprint":false},{"year":1993,"finding":"The R89Q missense mutation in IDUA results in reduced stability and activity of the mutant protein. The 678-7g→a splice site mutation allows a very small amount of normal mRNA to be produced, accounting for the mild (Scheie) phenotype. Both the 5' and 3' splice site mutations (1060+2t→c and 678-7g→a) result in high proportions of mature mRNAs containing introns.","method":"Chemical cleavage mutation detection, direct PCR sequencing, expression of R89Q in cells, RT-PCR of splice variants","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — expression studies with mutagenesis plus RT-PCR characterization of splice consequences, single lab with multiple orthogonal methods","pmids":["8213840"],"is_preprint":false},{"year":1998,"finding":"Polymorphic amino acid changes Q105 (R105Q), T361 (A361T), and I454 (V454I) individually and in combination increase alpha-L-iduronidase specific activity when expressed in COS-7 cells, demonstrating that these polymorphic positions modulate IDUA enzymatic activity.","method":"Site-directed mutagenesis of IDUA cDNA, expression in COS-7 cells, enzyme activity assay","journal":"Proceedings of the National Science Council, Republic of China. Part B, Life sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro expression with enzyme assay, single lab, single study","pmids":["9536518"],"is_preprint":false},{"year":2002,"finding":"Clinically approved aminoglycosides gentamicin, tobramycin, and amikacin can suppress naturally occurring IDUA premature stop mutations (disease-associated nonsense mutations) in a mammalian translation system, restoring full-length protein. Suppression efficiency is context-dependent, determined primarily by the tetranucleotide termination signal (stop codon plus +1 nucleotide).","method":"Readthrough reporter constructs and IDUA cDNA constructs with premature stop mutations in mammalian translation system, enzyme activity assay","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro mammalian translation system with both reporter and disease cDNA constructs, single lab","pmids":["12072912"],"is_preprint":false},{"year":2005,"finding":"Lentiviral-mediated IDUA gene transfer resulted in IDUA transgene expression highest in liver and spleen; secretion of corrective enzyme from these tissues into plasma allowed cross-correction of distant tissues (kidney, heart, lung) via uptake of secreted enzyme, demonstrating that 1% of normal IDUA activity is sufficient to normalize GAG levels in urine, liver, and spleen of MPS I mice.","method":"In vivo lentiviral vector injection (tail vein) in MPS I mice, PCR for integration, enzyme activity assay, GAG quantification in tissues","journal":"Human gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse model with enzyme activity, GAG quantification, and PCR localization of vector; single lab","pmids":["15703491"],"is_preprint":false},{"year":2010,"finding":"The knock-in Idua-W392X mouse (analogous to human IDUA-W402X) shows no detectable alpha-L-iduronidase activity, increased sulfated GAG excretion in urine and storage in multiple tissues, bone abnormalities, and altered metabolism, establishing this as a faithful model of MPS I-H with complete loss of lysosomal enzyme function.","method":"Gene targeting/knock-in, enzyme activity assay, GAG quantification, histology, electron microscopy, X-ray imaging","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (enzyme assay, biochemical GAG measurement, histology, EM) in a genetically defined animal model","pmids":["19751987"],"is_preprint":false},{"year":2011,"finding":"The designer aminoglycoside NB84 suppresses the Idua-W392X premature termination codon more efficiently than conventional aminoglycosides (gentamicin, G418, amikacin, paromomycin), restoring sufficient functional alpha-L-iduronidase activity to partially reverse lysosomal GAG accumulation in mouse embryonic fibroblasts and significantly reduce urine and tissue GAG storage in vivo.","method":"Suppression assay in mouse embryonic fibroblasts, enzyme activity assay, GAG quantification, in vivo drug administration to Idua-W392X mice","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — both in vitro (MEFs) and in vivo suppression with multiple drug comparisons and functional readouts (enzyme activity + GAG levels)","pmids":["22056610"],"is_preprint":false},{"year":2011,"finding":"Murine IDUA fused to the carboxyl terminus of a chimeric anti-transferrin receptor monoclonal antibody (cTfRMAb-IDUA fusion protein) retains comparable enzyme activity (776 ± 79 units/μg protein) to recombinant IDUA, crosses the blood-brain barrier via transferrin receptor-mediated transport, and reverses pre-existing lysosomal inclusion bodies in brain by 73% and reduces GAGs in peripheral tissues of MPS I mice.","method":"Fusion protein engineering, enzyme activity assay, intravenous administration to MPS I null mice, GAG quantification, semithin brain section quantitation of lysosomal inclusion bodies","journal":"Molecular pharmaceutics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzyme activity reconstitution of fusion protein plus in vivo functional correction with quantitative histological and biochemical readouts","pmids":["21667973"],"is_preprint":false},{"year":2011,"finding":"A novel IDUA splice site mutation (c.1727+3G>C) causes aberrant splicing of intron 12 (insertion of GTCC), introducing a frameshift and premature termination codon (p.Cys577SerfsX15), with the deleterious effect primarily due to C-terminal truncation. Additionally, exon 4 skipping is a normal alternative splicing event (25–34% of transcripts in healthy individuals), potentially regulating iduronidase activity levels.","method":"Sequence analysis of IDUA transcripts, RT-PCR of leukocyte RNA, gene expression studies","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — RT-PCR characterization of aberrant splicing product confirmed mechanistically, single lab","pmids":["21831683"],"is_preprint":false},{"year":2013,"finding":"Chloramphenicol treatment of MPS I patient fibroblasts (carrying p.W402X/p.W402X) produced a ~100-fold increase in IDUA activity; cDNA sequencing showed only alleles without the nonsense mutation were amplified even after treatment, indicating that nonsense alleles are targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than stop codon readthrough.","method":"Cell culture treatment of patient fibroblasts, IDUA enzyme activity assay, cDNA sequencing","journal":"Current pharmaceutical biotechnology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — enzyme activity assay plus molecular analysis of mRNA from patient cells, single lab","pmids":["23167761"],"is_preprint":false},{"year":2009,"finding":"Expression of novel MPS I mutations (including p.V620F, p.W626X) in Chinese hamster ovary (CHO) cells confirmed pathogenicity. Missense mutations localized to the hydrophobic core of IDUA are associated with severe phenotype, while surface-localized missense mutations cause attenuated phenotypes. Mutations in the C-terminal 130 amino acids cause clinical disease, establishing functional importance of the IDUA C-terminus.","method":"Transient expression in CHO cells, enzyme activity assay, 3D protein modeling","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based expression assays combined with structural analysis, single lab","pmids":["19396826"],"is_preprint":false},{"year":2011,"finding":"Novel p.E276K IDUA missense mutation significantly reduces alpha-L-iduronidase activity when expressed in COS-7 cells by transient transfection, confirming it as a disease-causing variant.","method":"Transient transfection of mutant IDUA construct into COS-7 cells, enzyme activity assay","journal":"Molecular vision","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct enzyme activity measurement from expressed mutant protein, single lab, single method","pmids":["21364962"],"is_preprint":false},{"year":2017,"finding":"The p.X654R (c.*1T>C) IDUA variant produces an mRNA encoding a protein with 38 additional amino acids (C-terminal extension); COS-7 cells expressing this variant show an elevated apparent molecular mass by Western blot and extremely low enzyme activity, while p.W312X and p.Q380X produce no detectable protein by Western blot. This established that p.X654R is a hypomorphic allele with residual activity resulting in intermediate MPS I.","method":"Expression in COS-7 cells, enzyme activity assay, Western blot, 3'RACE sequencing of mutant mRNA","journal":"Annals of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods (3'RACE, Western blot, enzyme assay) in single lab characterizing molecular consequence","pmids":["29282708"],"is_preprint":false},{"year":2014,"finding":"The p.L18P IDUA mutation alters the signal peptide structure (reducing it to 25 amino acids and altering its secondary structure), likely impairing lysosomal targeting of alpha-L-iduronidase, based on bioinformatics analysis of signal peptide properties and clinical correlation with attenuated phenotype featuring bone/cartilage symptoms without visceral or cognitive involvement.","method":"Bioinformatics signal peptide analysis, clinical phenotyping","journal":"Clinical genetics","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no direct experimental validation of altered localization","pmids":["25256405"],"is_preprint":false},{"year":2018,"finding":"Triazole-iduronic acid hybrid molecules synthesized by click chemistry were identified as the first small molecules that inhibit and thermally stabilize recombinant human alpha-L-iduronidase (rh-α-IDUA) in vitro, suggesting pharmacological chaperone potential.","method":"Enzyme inhibition assay, thermal denaturation/stability assay of rh-α-IDUA with library compounds","journal":"Chemical communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro enzyme and thermal stability assays, single lab, novel compound class identified","pmids":["29473068"],"is_preprint":false},{"year":2020,"finding":"A functional HEK293-based expression platform combining fluorescence-based alpha-iduronidase activity assay and semi-quantitative Western blotting determined that pseudodeficiency IDUA variants (p.His82Gln, p.Ala79Thr, p.Val322Glu, p.Asp223Asn) variably reduce but do not abolish specific activity, while pathogenic variants (p.Ser633Leu, p.His240Arg) show very low activity. p.His240Arg showed 5-fold higher specific activity than p.Ser633Leu despite both causing Scheie syndrome, and p.Ser586Phe and p.Ile272Leu VUS variants had specific activities in the pseudodeficiency range.","method":"Viral delivery of IDUA variants into IDUA-deficient HAP1 cells, single-cell cloning, enzyme activity assay, Western blot for protein quantification","journal":"International journal of neonatal screening","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct enzyme specific activity measurement from isogenic expression system with multiple variants, single lab","pmids":["33198351"],"is_preprint":false},{"year":2021,"finding":"Reduction of D-idua (Drosophila IDUA ortholog) by RNAi causes lethality at the pupal stage, increased lysosome number and size in brain and muscle, impaired lysosome acidification leading to dysfunctional lysosome-autophagosome fusion and autophagy flux blockade, and a metabolic shift toward glycolysis and lipogenesis. Starvation rescued both autophagy/lysosome phenotypes and metabolic alterations, establishing that IDUA deficiency causes secondary autophagy impairment and metabolic dysregulation.","method":"RNAi-mediated knockdown in Drosophila, lysosome staining and imaging, autophagy flux assay, metabolic pathway analysis, starvation rescue experiment","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vivo readouts (lethality, lysosome morphology, autophagy, metabolism) in Drosophila model with rescue experiment","pmids":["35011691"],"is_preprint":false},{"year":2022,"finding":"Injection of mutated z-idua-L346R mRNA into zebrafish embryos reduced z-Idua enzymatic activity and caused dominant negative defective phenotypes (compared to wild-type injected), while z-idua-E540-frameshift mRNA provided partial enzymatic activity and did not cause defective phenotypes, establishing that enzymatic activity of IDUA directly correlates with disease phenotype in this model system.","method":"Zebrafish morpholino knockdown, mRNA microinjection of mutant idua, z-Idua enzymatic activity assay, phenotypic scoring","journal":"Journal of personalized medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo zebrafish model with enzymatic activity measurement and phenotypic readout, single lab","pmids":["35893292"],"is_preprint":false},{"year":2023,"finding":"IDUA morpholino knockdown in zebrafish larvae upregulates TP53 signaling and LC3/GABARAP family protein-mediated autophagy, and upregulates leukotriene A4 hydrolase-mediated arachidonic acid metabolism; introduction of wild-type human IDUA mRNA rescued developmental defects and aberrant signaling, placing IDUA upstream of these pathways.","method":"Zebrafish IDUA morpholino knockdown, transcriptome profiling, rescue with wild-type IDUA mRNA, IDUA enzyme activity assay","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomic pathway analysis with mRNA rescue validation in vivo, single lab","pmids":["37347427"],"is_preprint":false},{"year":2024,"finding":"Heterozygous loss-of-function mutations in IDUA have a gene-dosage effect on Aβ40 levels in brain interstitial fluid in C57BL/6 mice and significantly increase Aβ plaque formation in the 5xFAD Alzheimer's disease mouse model, establishing that partial IDUA deficiency is sufficient to perturb amyloid processing.","method":"In vivo mouse genetics (IDUA heterozygous knock-out crossed with 5xFAD), brain interstitial fluid Aβ40 measurement, amyloid plaque quantification","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo mouse genetic model with direct biochemical readout, single preprint study not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2024,"finding":"Characterization of over 30 IDUA variants using HEK293 expression platform revealed that different variants have distinct effects on enzyme folding, processing, and stability (not just catalytic activity), and that relative specific activity serves as a first-level functional classifier. Some variants reduce activity primarily through folding/stability defects rather than direct catalytic impairment.","method":"HEK293-based expression of IDUA variants, fluorescence enzyme activity assay, semi-quantitative Western blotting for protein folding/processing assessment","journal":"NPJ genomic medicine","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct enzyme activity plus protein quantification across >30 variants, single lab with orthogonal methods","pmids":["39702574"],"is_preprint":false},{"year":2024,"finding":"The novel IDUA splice variant c.159-9T>A causes two aberrant splicing events—exon 2 skipping and intron 1 retention—as demonstrated by minigene splicing assay, establishing the molecular consequence of this mutation on IDUA mRNA processing.","method":"Minigene splicing assay, WES, SNP array, Sanger sequencing","journal":"Molecular genetics & genomic medicine","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct minigene functional assay demonstrating aberrant splicing, single lab","pmids":["39132856"],"is_preprint":false},{"year":2025,"finding":"The novel IDUA deletion p.His356_Gln362del disrupts the protein's substrate-binding site, causing structural deformation and complete loss of enzymatic activity; the missense mutation p.Pro533Arg affects protein stability and flexibility by introducing a bulkier arginine residue that interferes with the contact region between the β-sheet structure and substrate-bound helix, reducing substrate affinity.","method":"Sanger sequencing, SWISS-MODEL structural homology modeling, DynaMut stability prediction, clinical phenotyping","journal":"Molecular genetics and metabolism reports","confidence":"Low","confidence_rationale":"Tier 4 / Weak — structural analysis primarily computational, no direct enzyme activity measurement reported for the novel deletion variant","pmids":["40291162"],"is_preprint":false},{"year":2025,"finding":"Combining two or more clinically benign IDUA variants in cis on a single allele reduces the specific activity of the resulting enzyme into the pathogenic range (comparable to attenuated or severe MPS I-associated variants), as measured by the established HAP1-cell functional platform.","method":"Viral delivery of single and combined IDUA variant constructs into IDUA-deficient HAP1 cells, single-cell cloning, enzyme specific activity assay, Western blot","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct enzyme specific activity measurement from isogenic expression system, single lab","pmids":["40359731"],"is_preprint":false}],"current_model":"IDUA encodes alpha-L-iduronidase, a lysosomal hydrolase that degrades glycosaminoglycans heparan sulfate and dermatan sulfate; the enzyme is translated with a signal peptide directing it to lysosomes, requires correct folding and C-terminal integrity for activity, and loss-of-function mutations spanning missense, nonsense, frameshift, and splice-site classes all cause MPS I by abolishing or severely reducing enzymatic activity, which blocks lysosomal GAG catabolism and secondarily impairs autophagy flux, activates TP53 and autophagy signaling pathways, and—at the heterozygous level—modulates amyloid β processing in mouse models."},"narrative":{"mechanistic_narrative":"IDUA encodes alpha-L-iduronidase, a lysosomal hydrolase that degrades the glycosaminoglycans heparan sulfate and dermatan sulfate, and loss of its activity causes the lysosomal storage disorder mucopolysaccharidosis type I (MPS I) [PMID:2220820, PMID:19751987]. The enzyme is translated with a signal peptide that directs it to the lysosome, and a mutation reducing and restructuring this signal peptide is associated with an attenuated, predominantly skeletal phenotype [PMID:25256405]. The IDUA locus has a housekeeping-gene architecture (GC-rich, Sp1-bound promoter lacking TATA/CAAT motifs) [PMID:1339393]. Disease-causing lesions span the full allelic spectrum — missense, nonsense, frameshift, and splice-site mutations — and act through distinct molecular routes: destabilizing the folded protein, disrupting the substrate-binding site, abolishing protein production, or generating aberrantly spliced transcripts with intron retention, exon skipping, or premature termination codons [PMID:8328452, PMID:8213840, PMID:19396826, PMID:29282708, PMID:39132856]. Catalytic activity correlates directly with clinical severity; missense changes in the hydrophobic core and the C-terminal ~130 residues are severe, surface changes are attenuated, and folding/stability defects rather than direct catalytic impairment underlie many hypomorphic alleles [PMID:19396826, PMID:39702574]. Enzyme specific activity provides a quantitative functional classifier that separates pathogenic, pseudodeficiency, and benign variants, and combinations of individually benign variants in cis can drop activity into the pathogenic range [PMID:33198351, PMID:40359731]. Loss of IDUA blocks lysosomal GAG catabolism and secondarily impairs lysosomal acidification and autophagosome-lysosome fusion, blocking autophagy flux and shifting metabolism toward glycolysis and lipogenesis [PMID:35011691]; in vivo it acts upstream of TP53 and LC3/GABARAP-mediated autophagy signaling [PMID:37347427]. Because secreted enzyme can be taken up by distant tissues, as little as 1% of normal activity normalizes GAG storage, a principle that underlies enzyme-replacement, gene-transfer, and nonsense-suppression therapeutic strategies [PMID:15703491, PMID:22056610].","teleology":[{"year":1990,"claim":"Establishing that IDUA encodes the lysosomal hydrolase degrading heparan and dermatan sulfate and mapping it to 4p16.3 anchored the gene to its enzymatic function and chromosomal location.","evidence":"In situ hybridization and Southern blot of human-mouse hybrids with enzyme activity assay","pmids":["2220820"],"confidence":"High","gaps":["Did not define gene structure or catalytic mechanism","No mutation-to-phenotype correlation yet"]},{"year":1992,"claim":"Cloning the orthologous canine gene revealed a 14-exon housekeeping-gene architecture and showed a splice-donor mutation causes intron retention and premature termination, framing how splice lesions disrupt IDUA.","evidence":"Gene cloning, RT-PCR, primer extension and genomic sequencing in canine MPS I","pmids":["1339393"],"confidence":"High","gaps":["Human gene structure inferred by analogy","Did not address protein folding or substrate binding"]},{"year":1993,"claim":"Expression of mutagenized human cDNAs established that individual IDUA mutations produce distinct molecular consequences — trace activity, residual activity, low mRNA, exon skipping, cryptic splicing — explaining phenotypic variability from mild Scheie to severe disease.","evidence":"Transfection of mutant cDNAs into COS cells, enzyme assays, RT-PCR splice analysis; chemical-cleavage mutation detection","pmids":["8328452","8213840"],"confidence":"High","gaps":["Limited number of variants","No structural basis for activity loss"]},{"year":1998,"claim":"Polymorphic residues were shown to modulate enzyme specific activity, indicating sequence context tunes IDUA output beyond simple loss-of-function.","evidence":"Site-directed mutagenesis and expression in COS-7 cells with activity assays","pmids":["9536518"],"confidence":"Medium","gaps":["Single study","Physiological relevance of activity gains unclear"]},{"year":2002,"claim":"Demonstrating that clinical aminoglycosides suppress IDUA nonsense mutations to restore full-length protein opened nonsense-readthrough as a therapeutic avenue and identified the termination context as the key determinant.","evidence":"Readthrough reporter and IDUA premature-stop cDNA constructs in a mammalian translation system","pmids":["12072912"],"confidence":"Medium","gaps":["In vitro only","Suppression efficiency low and context-dependent"]},{"year":2005,"claim":"Lentiviral gene transfer in MPS I mice showed secreted enzyme cross-corrects distant tissues and that 1% of normal activity suffices to normalize GAG, defining the therapeutic threshold and metabolic cross-correction principle.","evidence":"In vivo lentiviral delivery in MPS I mice with vector PCR, enzyme assay, tissue GAG quantification","pmids":["15703491"],"confidence":"Medium","gaps":["CNS correction not addressed","Durability and integration safety not resolved"]},{"year":2009,"claim":"Combining expression assays with structural modeling established that core-localized missense mutations are severe while surface mutations are attenuated, and that the C-terminal ~130 residues are functionally essential.","evidence":"Transient CHO expression with enzyme assays and 3D protein modeling of MPS I variants","pmids":["19396826"],"confidence":"Medium","gaps":["Modeling-based structural inference","Folding versus catalytic contributions not separated"]},{"year":2010,"claim":"The Idua-W392X knock-in mouse provided a faithful null model recapitulating MPS I-H biochemistry and pathology, enabling mechanistic and preclinical work.","evidence":"Gene-targeted knock-in with enzyme assay, GAG quantification, histology, EM, and X-ray imaging","pmids":["19751987"],"confidence":"High","gaps":["Models a single nonsense allele","Secondary cellular pathways not dissected"]},{"year":2011,"claim":"Designer aminoglycoside NB84 and a blood-brain-barrier-penetrant antibody-IDUA fusion demonstrated that both stop-codon suppression and receptor-mediated brain delivery can restore activity and reverse storage in vivo, including in the CNS.","evidence":"Suppression assays in MEFs and Idua-W392X mice; cTfRMAb-IDUA fusion enzyme activity and intravenous correction with brain inclusion-body quantitation","pmids":["22056610","21667973"],"confidence":"High","gaps":["Long-term efficacy and toxicity unaddressed","Limited to specific alleles/delivery systems"]},{"year":2011,"claim":"Characterization of novel missense and splice variants (p.E276K; c.1727+3G>C) confirmed pathogenicity and showed C-terminal truncation is the deleterious driver, while documenting exon 4 skipping as a normal regulatory splicing event.","evidence":"COS-7 transient expression with enzyme assays; RT-PCR transcript analysis of leukocyte RNA","pmids":["21364962","21831683"],"confidence":"Medium","gaps":["Function of physiological exon-4 skipping unproven","Single-variant resolution"]},{"year":2013,"claim":"Chloramphenicol's ~100-fold activity increase in W402X patient fibroblasts, with no detectable nonsense allele transcript, revealed that nonsense alleles undergo nonsense-mediated decay and that some drugs act independently of readthrough.","evidence":"Patient fibroblast drug treatment, enzyme assay, and cDNA sequencing","pmids":["23167761"],"confidence":"Medium","gaps":["Mechanism of chloramphenicol action undefined","Single cell line/genotype"]},{"year":2017,"claim":"The C-terminally extended p.X654R allele was shown to produce an enlarged, near-inactive protein causing intermediate MPS I, while nonsense variants yielded no detectable protein, refining genotype-phenotype rules for hypomorphic alleles.","evidence":"COS-7 expression, enzyme assay, Western blot, and 3'RACE of mutant mRNA","pmids":["29282708"],"confidence":"Medium","gaps":["Mechanism of activity loss from C-terminal extension not detailed","Single lab"]},{"year":2020,"claim":"An isogenic HAP1/HEK293 expression platform quantitatively distinguished pseudodeficiency, pathogenic, and VUS variants by specific activity, providing a functional framework for newborn-screening interpretation.","evidence":"Viral delivery of variants into IDUA-deficient HAP1 cells, single-cell cloning, fluorescence activity assay, Western blot","pmids":["33198351"],"confidence":"Medium","gaps":["Recombinant expression may not capture tissue context","Single-lab platform"]},{"year":2021,"claim":"Drosophila IDUA knockdown linked enzyme loss to impaired lysosome acidification, blocked autophagosome-lysosome fusion, and a glycolytic/lipogenic metabolic shift, all reversible by starvation, establishing secondary autophagy and metabolic dysregulation downstream of IDUA deficiency.","evidence":"RNAi knockdown in Drosophila with lysosome imaging, autophagy flux assays, metabolic analysis, and starvation rescue","pmids":["35011691"],"confidence":"Medium","gaps":["Ortholog model","Direct relevance of metabolic shift to human MPS I unconfirmed"]},{"year":2022,"claim":"Zebrafish mRNA injection showed enzymatic activity correlates directly with phenotype, with a dominant-negative allele (z-idua-L346R) and a residual-activity frameshift allele behaving differently, reinforcing activity as the disease determinant.","evidence":"Zebrafish morpholino knockdown and mutant mRNA microinjection with enzyme assays and phenotypic scoring","pmids":["35893292"],"confidence":"Medium","gaps":["Dominant-negative mechanism not molecularly defined","Ortholog model"]},{"year":2023,"claim":"Zebrafish knockdown and human IDUA mRNA rescue placed IDUA upstream of TP53 signaling, LC3/GABARAP autophagy, and leukotriene A4 hydrolase-mediated arachidonic acid metabolism, connecting enzyme loss to defined signaling cascades.","evidence":"Zebrafish IDUA morpholino knockdown, transcriptome profiling, and wild-type mRNA rescue","pmids":["37347427"],"confidence":"Medium","gaps":["Mechanistic links between GAG storage and TP53/autophagy unproven","Transcriptome correlations not validated at protein level"]},{"year":2024,"claim":"Systematic characterization of over 30 variants showed many act through folding, processing, and stability defects rather than direct catalytic loss, establishing relative specific activity as a first-level functional classifier.","evidence":"HEK293 expression of >30 variants with fluorescence activity assay and semi-quantitative Western blotting","pmids":["39702574"],"confidence":"Medium","gaps":["Folding defects inferred from protein abundance, not direct biophysics","Single-lab platform"]},{"year":2024,"claim":"Heterozygous IDUA loss-of-function exerted a gene-dosage effect on brain Abeta40 and increased plaque burden in the 5xFAD model, implicating partial IDUA deficiency in amyloid processing beyond classic MPS I.","evidence":"Mouse genetics (IDUA heterozygous knockout crossed with 5xFAD), interstitial fluid Abeta40 measurement, plaque quantification (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Mechanism linking IDUA to amyloid metabolism unknown"]},{"year":2025,"claim":"Demonstrating that combinations of individually benign IDUA variants in cis lower activity into the pathogenic range showed complex-allele additivity as a genotype mechanism in MPS I.","evidence":"Viral delivery of single and combined variant constructs in HAP1 cells with specific activity assay and Western blot","pmids":["40359731"],"confidence":"Medium","gaps":["Recombinant system; clinical cases of such complex alleles not confirmed","Single lab"]},{"year":null,"claim":"How GAG storage mechanistically triggers TP53 activation, autophagy blockade, metabolic reprogramming, and altered amyloid processing — and whether these secondary pathways are therapeutic targets in human MPS I — remains unresolved.","evidence":"Open question synthesized across ortholog and mouse studies","pmids":[],"confidence":"Low","gaps":["No direct mechanistic link from GAG accumulation to TP53/autophagy in human cells","Amyloid finding is a single preprint","No structural model defining catalytic versus stability determinants experimentally validated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,7,17,22]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,24]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,7,18]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[18]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[18,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35475","full_name":"Alpha-L-iduronidase","aliases":[],"length_aa":653,"mass_kda":72.7,"function":"","subcellular_location":"Lysosome","url":"https://www.uniprot.org/uniprotkb/P35475/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IDUA","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IDUA","total_profiled":1310},"omim":[{"mim_id":"619345","title":"DYSOSTOSIS MULTIPLEX, AIN-NAZ TYPE; DMAN","url":"https://www.omim.org/entry/619345"},{"mim_id":"607016","title":"SCHEIE SYNDROME","url":"https://www.omim.org/entry/607016"},{"mim_id":"607015","title":"HURLER-SCHEIE SYNDROME","url":"https://www.omim.org/entry/607015"},{"mim_id":"607014","title":"HURLER SYNDROME","url":"https://www.omim.org/entry/607014"},{"mim_id":"253600","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","url":"https://www.omim.org/entry/253600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IDUA"},"hgnc":{"alias_symbol":["MPS1","MPSI"],"prev_symbol":[]},"alphafold":{"accession":"P35475","domains":[{"cath_id":"2.60.40.1500","chopping":"31-43_400-542","consensus_level":"medium","plddt":98.1778,"start":31,"end":542},{"cath_id":"3.20.20.80","chopping":"50-389","consensus_level":"medium","plddt":97.2052,"start":50,"end":389},{"cath_id":"2.60.40.10","chopping":"553-639","consensus_level":"high","plddt":98.1397,"start":553,"end":639}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35475","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35475-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35475-F1-predicted_aligned_error_v6.png","plddt_mean":94.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IDUA","jax_strain_url":"https://www.jax.org/strain/search?query=IDUA"},"sequence":{"accession":"P35475","fasta_url":"https://rest.uniprot.org/uniprotkb/P35475.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35475/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35475"}},"corpus_meta":[{"pmid":"12072912","id":"PMC_12072912","title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.","date":"2002","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/12072912","citation_count":116,"is_preprint":false},{"pmid":"8328452","id":"PMC_8328452","title":"Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area.","date":"1993","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8328452","citation_count":84,"is_preprint":false},{"pmid":"1339393","id":"PMC_1339393","title":"Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1339393","citation_count":81,"is_preprint":false},{"pmid":"33390939","id":"PMC_33390939","title":"Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33390939","citation_count":80,"is_preprint":false},{"pmid":"8213840","id":"PMC_8213840","title":"Identification of mutations in the alpha-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes.","date":"1993","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8213840","citation_count":80,"is_preprint":false},{"pmid":"30589437","id":"PMC_30589437","title":"Inulin Ameliorates Alcoholic Liver Disease via Suppressing LPS-TLR4-Mψ Axis and Modulating Gut Microbiota in Mice.","date":"2019","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/30589437","citation_count":73,"is_preprint":false},{"pmid":"2220820","id":"PMC_2220820","title":"Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3.","date":"1990","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2220820","citation_count":71,"is_preprint":false},{"pmid":"15703491","id":"PMC_15703491","title":"Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector.","date":"2005","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15703491","citation_count":61,"is_preprint":false},{"pmid":"21394825","id":"PMC_21394825","title":"IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel α-L-iduronidase (IDUA) alleles.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21394825","citation_count":59,"is_preprint":false},{"pmid":"22056610","id":"PMC_22056610","title":"The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22056610","citation_count":58,"is_preprint":false},{"pmid":"21667973","id":"PMC_21667973","title":"Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.","date":"2011","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/21667973","citation_count":54,"is_preprint":false},{"pmid":"19751987","id":"PMC_19751987","title":"Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.","date":"2010","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19751987","citation_count":51,"is_preprint":false},{"pmid":"29393969","id":"PMC_29393969","title":"Worldwide distribution of common IDUA pathogenic variants.","date":"2018","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29393969","citation_count":32,"is_preprint":false},{"pmid":"12509712","id":"PMC_12509712","title":"Diversity of mutations and distribution of single nucleotide polymorphic alleles in the human alpha-L-iduronidase (IDUA) gene.","date":"2002","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12509712","citation_count":31,"is_preprint":false},{"pmid":"19396826","id":"PMC_19396826","title":"Mucopolysaccharidosis type I in 21 Czech and Slovak patients: mutation analysis suggests a functional importance of C-terminus of the IDUA protein.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19396826","citation_count":29,"is_preprint":false},{"pmid":"10515997","id":"PMC_10515997","title":"An Mpsi-containing heterologous RNA, but not env mRNA, is efficiently packaged into avian retroviral particles.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10515997","citation_count":28,"is_preprint":false},{"pmid":"26256109","id":"PMC_26256109","title":"Identification of IDUA and WNT16 Phosphorylation-Related Non-Synonymous Polymorphisms for Bone Mineral Density in Meta-Analyses of Genome-Wide Association Studies.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26256109","citation_count":24,"is_preprint":false},{"pmid":"36232472","id":"PMC_36232472","title":"MPSI Manifestations and Treatment Outcome: Skeletal Focus.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232472","citation_count":18,"is_preprint":false},{"pmid":"31060789","id":"PMC_31060789","title":"Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.","date":"2019","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31060789","citation_count":18,"is_preprint":false},{"pmid":"28752568","id":"PMC_28752568","title":"IDUA mutational profile and genotype-phenotype relationships in UK patients with Mucopolysaccharidosis Type I.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28752568","citation_count":17,"is_preprint":false},{"pmid":"23167761","id":"PMC_23167761","title":"Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients.","date":"2013","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/23167761","citation_count":16,"is_preprint":false},{"pmid":"1682883","id":"PMC_1682883","title":"PCR of a KpnI RFLP in the alpha-L-iduronidase (IDUA) gene.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1682883","citation_count":15,"is_preprint":false},{"pmid":"28842642","id":"PMC_28842642","title":"Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28842642","citation_count":14,"is_preprint":false},{"pmid":"27511503","id":"PMC_27511503","title":"Evaluation and identification of IDUA gene mutations in Turkishpatients with mucopolysaccharidosis type I.","date":"2016","source":"Turkish journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27511503","citation_count":12,"is_preprint":false},{"pmid":"1533802","id":"PMC_1533802","title":"Linkage, but not gene order, of homologous loci, including alpha-L-iduronidase (Idua), is conserved in the Huntington disease region of the mouse and human genomes.","date":"1992","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/1533802","citation_count":12,"is_preprint":false},{"pmid":"32542182","id":"PMC_32542182","title":"Ocular Tolerability and Immune Response to Corneal Intrastromal AAV-IDUA Gene Therapy in New Zealand White Rabbits.","date":"2020","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/32542182","citation_count":11,"is_preprint":false},{"pmid":"28608934","id":"PMC_28608934","title":"An Integrated Computational Framework to Assess the Mutational Landscape of α-L-Iduronidase IDUA Gene.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28608934","citation_count":11,"is_preprint":false},{"pmid":"29473068","id":"PMC_29473068","title":"A combinatorial approach towards the synthesis of non-hydrolysable triazole-iduronic acid hybrid inhibitors of human α-l-iduronidase: discovery of enzyme stabilizers for the potential treatment of MPSI.","date":"2018","source":"Chemical communications (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29473068","citation_count":11,"is_preprint":false},{"pmid":"1362562","id":"PMC_1362562","title":"PCR detection of two RFLPs in exon I of the alpha-L-iduronidase (IDUA) gene.","date":"1992","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1362562","citation_count":10,"is_preprint":false},{"pmid":"35011691","id":"PMC_35011691","title":"Drosophila D-idua Reduction Mimics Mucopolysaccharidosis Type I Disease-Related Phenotypes.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35011691","citation_count":9,"is_preprint":false},{"pmid":"21364962","id":"PMC_21364962","title":"A novel p.E276K IDUA mutation decreasing α-L-iduronidase activity causes mucopolysaccharidosis type I.","date":"2011","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/21364962","citation_count":9,"is_preprint":false},{"pmid":"22472595","id":"PMC_22472595","title":"Intracerebroventricular transplantation of human bone marrow-derived multipotent progenitor cells in an immunodeficient mouse model of mucopolysaccharidosis type I (MPS-I).","date":"2012","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/22472595","citation_count":9,"is_preprint":false},{"pmid":"31473686","id":"PMC_31473686","title":"Mapping of IDUA gene variants in Pakistani patients with mucopolysaccharidosis type 1.","date":"2019","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/31473686","citation_count":8,"is_preprint":false},{"pmid":"34746235","id":"PMC_34746235","title":"Which Is the Best In Silico Program for the Missense Variations in IDUA Gene? A Comparison of 33 Programs Plus a Conservation Score and Evaluation of 586 Missense Variants.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34746235","citation_count":8,"is_preprint":false},{"pmid":"23418953","id":"PMC_23418953","title":"Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration.","date":"2013","source":"Journal of microencapsulation","url":"https://pubmed.ncbi.nlm.nih.gov/23418953","citation_count":8,"is_preprint":false},{"pmid":"27766162","id":"PMC_27766162","title":"Maternal mosaicism for IDUA deletion clarifies recurrence risk in MPS I.","date":"2016","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/27766162","citation_count":7,"is_preprint":false},{"pmid":"25256405","id":"PMC_25256405","title":"p.L18P: a novel IDUA mutation that causes a distinct attenuated phenotype in mucopolysaccharidosis type I patients.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25256405","citation_count":7,"is_preprint":false},{"pmid":"29282708","id":"PMC_29282708","title":"p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells.","date":"2017","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29282708","citation_count":6,"is_preprint":false},{"pmid":"32785987","id":"PMC_32785987","title":"A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I.","date":"2020","source":"Journal of veterinary internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32785987","citation_count":6,"is_preprint":false},{"pmid":"22520214","id":"PMC_22520214","title":"Treatment of adult MPSI mouse brains with IDUA-expressing mesenchymal stem cells decreases GAG deposition and improves exploratory behavior.","date":"2012","source":"Genetic vaccines and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22520214","citation_count":5,"is_preprint":false},{"pmid":"31275456","id":"PMC_31275456","title":"Associations of IDUA and PTCH1 with Bone Mineral Density, Bone Turnover Markers, and Fractures in Chinese Elderly Patients with Osteoporosis.","date":"2019","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/31275456","citation_count":5,"is_preprint":false},{"pmid":"39702574","id":"PMC_39702574","title":"Functional assessment of IDUA variants of uncertain significance identified by newborn screening.","date":"2024","source":"NPJ genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39702574","citation_count":4,"is_preprint":false},{"pmid":"31298590","id":"PMC_31298590","title":"Mutation Analysis of the IDUA Gene in Iranian Patients with Mucopolysaccharidosis Type 1: Identification of Four Novel Mutations.","date":"2019","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/31298590","citation_count":4,"is_preprint":false},{"pmid":"33198351","id":"PMC_33198351","title":"A Biochemical Platform to Define the Relative Specific Activity of IDUA Variants Identified by Newborn Screening.","date":"2020","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/33198351","citation_count":4,"is_preprint":false},{"pmid":"31758674","id":"PMC_31758674","title":"Identification of a novel compound heterozygous IDUA mutation underlies Mucopolysaccharidoses type I in a Chinese pedigree.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31758674","citation_count":4,"is_preprint":false},{"pmid":"31319022","id":"PMC_31319022","title":"\"Missing mutations\" in MPS I: Identification of two novel copy number variations by an IDUA-specific in house MLPA assay.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31319022","citation_count":4,"is_preprint":false},{"pmid":"29843745","id":"PMC_29843745","title":"Novel splice site IDUA gene mutation in Tunisian pedigrees with hurler syndrome.","date":"2018","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29843745","citation_count":3,"is_preprint":false},{"pmid":"28649516","id":"PMC_28649516","title":"Novel frameshift variant in the IDUA gene underlies Mucopolysaccharidoses type I in a consanguineous Yemeni pedigree.","date":"2017","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/28649516","citation_count":3,"is_preprint":false},{"pmid":"37473537","id":"PMC_37473537","title":"Phenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice.","date":"2023","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37473537","citation_count":2,"is_preprint":false},{"pmid":"9536518","id":"PMC_9536518","title":"Human alpha-L-iduronidase (IDUA) gene: correlation of polymorphic DNA haplotype and IDUA activity in Chinese population.","date":"1998","source":"Proceedings of the National Science Council, Republic of China. Part B, Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9536518","citation_count":2,"is_preprint":false},{"pmid":"21831683","id":"PMC_21831683","title":"A novel mucopolysaccharidosis type I associated splice site mutation and IDUA splice variants.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21831683","citation_count":2,"is_preprint":false},{"pmid":"35893292","id":"PMC_35893292","title":"Quantification of Idua Enzymatic Activity Combined with Observation of Phenotypic Change in Zebrafish Embryos Provide a Preliminary Assessment of Mutated idua Correlated with Mucopolysaccharidosis Type I.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35893292","citation_count":2,"is_preprint":false},{"pmid":"39132856","id":"PMC_39132856","title":"Whole paternal uniparental disomy of chromosome 4 with a novel homozygous IDUA splicing variant, c.159-9T>A, in a Chinese patient with mucopolysaccharidosis type I.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39132856","citation_count":2,"is_preprint":false},{"pmid":"39559959","id":"PMC_39559959","title":"Long-Term Health Outcomes of Individuals With Pseudodeficiency Alleles in IDUA May Inform Newborn Screening Practices for Mucopolysaccharidosis Type I.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39559959","citation_count":2,"is_preprint":false},{"pmid":"34285554","id":"PMC_34285554","title":"IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis.","date":"2021","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34285554","citation_count":1,"is_preprint":false},{"pmid":"39687731","id":"PMC_39687731","title":"Intrathecal or intravenous AAV9-IDUA/RGX-111 at minimal effective dose prevents cardiac, skeletal and neurologic manifestations of murine MPS I.","date":"2024","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/39687731","citation_count":1,"is_preprint":false},{"pmid":"37347427","id":"PMC_37347427","title":"Identification of an α-l-iduronidase (IDUA) M1T mutation in a Chinese family with autosomal recessive mucopolysaccharidosis I.","date":"2023","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37347427","citation_count":1,"is_preprint":false},{"pmid":"27335677","id":"PMC_27335677","title":"Efficient IDUA Gene Mutation Detection with Combined Use of dHPLC and Dried Blood Samples.","date":"2013","source":"ISRN molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27335677","citation_count":1,"is_preprint":false},{"pmid":"28604952","id":"PMC_28604952","title":"[IDUA gene mutation analysis and prenatal diagnosis of two families affected with mucopolysaccharidosis type I].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28604952","citation_count":1,"is_preprint":false},{"pmid":"10596456","id":"PMC_10596456","title":"Linkage disequilibrium between IDUA kpnI-VNTR haplotype in Mexican patients with MPS-I.","date":"1999","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/10596456","citation_count":1,"is_preprint":false},{"pmid":"41272769","id":"PMC_41272769","title":"Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/41272769","citation_count":1,"is_preprint":false},{"pmid":"40359731","id":"PMC_40359731","title":"Combining clinically benign IDUA variants in cis reduces enzymatic activity of the resulting enzyme within the pathogenic range.","date":"2025","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40359731","citation_count":1,"is_preprint":false},{"pmid":"29323855","id":"PMC_29323855","title":"Analysis of the env gene variability of the IDU-A HIV-1 variant in the outbreak of the HIV infection epidemic in Perm region of Russia (1996-2011).","date":"2016","source":"Voprosy virusologii","url":"https://pubmed.ncbi.nlm.nih.gov/29323855","citation_count":1,"is_preprint":false},{"pmid":"40291162","id":"PMC_40291162","title":"Genetic variations in the IDUA gene in Tunisian MPS I families: Identification of a novel microdeletion disrupting substrate binding and structural insights.","date":"2025","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/40291162","citation_count":0,"is_preprint":false},{"pmid":"41283362","id":"PMC_41283362","title":"Reclassifying IDUA c.250G>A (p.Gly84Ser): Evidence for a Possible Pseudodeficiency Allele.","date":"2025","source":"International journal of neonatal screening","url":"https://pubmed.ncbi.nlm.nih.gov/41283362","citation_count":0,"is_preprint":false},{"pmid":"9700243","id":"PMC_9700243","title":"Human alpha-L-iduronidase (IDUA) gene: apparent recombination in intron 2 by haplotype analysis in a Taiwanese population.","date":"1998","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/9700243","citation_count":0,"is_preprint":false},{"pmid":"42161901","id":"PMC_42161901","title":"Homozygous R383H variant in IDUA gene causing pericentric retinitis pigmentosa in attenuated mucopolysaccharidosis type I.","date":"2026","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/42161901","citation_count":0,"is_preprint":false},{"pmid":"15953403","id":"PMC_15953403","title":"Haplotypes Eco47 III-Nsp I sites frequencies on the IDUA gene in Mexican native population.","date":"2005","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15953403","citation_count":0,"is_preprint":false},{"pmid":"25558755","id":"PMC_25558755","title":"Mutation c.1190-1delG/N in intron 8 and c.1708G>C/N in exon 12 not reported in the IDUA gene developed a clinical phenotype of Scheie syndrome.","date":"2014","source":"Investigacion clinica","url":"https://pubmed.ncbi.nlm.nih.gov/25558755","citation_count":0,"is_preprint":false},{"pmid":"36184100","id":"PMC_36184100","title":"[Analysis of a child with mucopolysaccharidoses type I due to compound heterozygous variants of IDUA gene].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36184100","citation_count":0,"is_preprint":false},{"pmid":"41837196","id":"PMC_41837196","title":"Case Report: Compound heterozygous mutations in the IDUA gene causing mucopolysaccharidosis type I with uterine developmental abnormality.","date":"2026","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41837196","citation_count":0,"is_preprint":false},{"pmid":"42190545","id":"PMC_42190545","title":"Variant classification for mucopolysaccharidosis type I; ACMG/AMP specification for IDUA from the ClinGen lysosomal diseases variant curation expert panel.","date":"2026","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/42190545","citation_count":0,"is_preprint":false},{"pmid":"41226457","id":"PMC_41226457","title":"Congenital Dermal Melanocytosis Exhibited in Two Patients with Hurler Syndrome: Clinical Characterization and Report of a Recurrent IDUA Allele in Colombia.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41226457","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.29.691286","title":"Protein Compositional Ratio Representation (PCRR) Systematically Improves Human Disease Prediction","date":"2025-12-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.29.691286","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.16.623962","title":"Haploinsufficiency of lysosomal enzyme genes in Alzheimer’s disease","date":"2024-11-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.16.623962","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38497,"output_tokens":6278,"usd":0.10483,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15379,"output_tokens":5485,"usd":0.10701,"stage2_stop_reason":"end_turn"},"total_usd":0.21184,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"IDUA (alpha-L-iduronidase) was chromosomally localized to human chromosome 4p16.3 by in situ hybridization and Southern blot analysis of human-mouse hybrid cell lines, confirming IDUA encodes the lysosomal hydrolase responsible for degrading glycosaminoglycans heparan sulfate and dermatan sulfate.\",\n      \"method\": \"In situ hybridization, Southern blot analysis of human-mouse somatic cell hybrids, enzyme activity assay\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (in situ hybridization, Southern blot, hybrid cell enzyme activity), replicated finding\",\n      \"pmids\": [\"2220820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The canine IDUA gene contains 14 exons spanning 13 kb, has a GC-rich promoter with Sp1 binding sites but no TATA box or CAAT motif (housekeeping gene architecture), and the canine MPS I mutation is a G→A transition at the donor splice site of intron 1, causing intron 1 retention in the RNA and a premature termination codon at the exon-intron junction.\",\n      \"method\": \"Gene cloning, restriction analysis, RT-PCR, primer extension, sequence analysis of genomic DNA\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct sequencing plus RT-PCR confirmation of aberrant RNA product, mutation confirmed by restriction analysis\",\n      \"pmids\": [\"1339393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Missense mutations Thr366→Pro and Ter→Cys in IDUA permit expression of only trace alpha-L-iduronidase activity; Gly409→Arg permits expression of ~60% normal activity. Nonsense mutation Tyr64→Ter causes very low mRNA levels and exon 2 skipping; Gln310→Ter causes use of a cryptic splice site. Established that specific IDUA mutations have distinct molecular consequences on RNA processing and enzyme activity.\",\n      \"method\": \"Transfection of mutagenized cDNAs into COS-1 cells, enzyme activity assay, RT-PCR analysis of RNA processing\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct expression of mutagenized cDNAs with enzyme activity measurements, combined with RNA processing analysis\",\n      \"pmids\": [\"8328452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The R89Q missense mutation in IDUA results in reduced stability and activity of the mutant protein. The 678-7g→a splice site mutation allows a very small amount of normal mRNA to be produced, accounting for the mild (Scheie) phenotype. Both the 5' and 3' splice site mutations (1060+2t→c and 678-7g→a) result in high proportions of mature mRNAs containing introns.\",\n      \"method\": \"Chemical cleavage mutation detection, direct PCR sequencing, expression of R89Q in cells, RT-PCR of splice variants\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — expression studies with mutagenesis plus RT-PCR characterization of splice consequences, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"8213840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Polymorphic amino acid changes Q105 (R105Q), T361 (A361T), and I454 (V454I) individually and in combination increase alpha-L-iduronidase specific activity when expressed in COS-7 cells, demonstrating that these polymorphic positions modulate IDUA enzymatic activity.\",\n      \"method\": \"Site-directed mutagenesis of IDUA cDNA, expression in COS-7 cells, enzyme activity assay\",\n      \"journal\": \"Proceedings of the National Science Council, Republic of China. Part B, Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro expression with enzyme assay, single lab, single study\",\n      \"pmids\": [\"9536518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Clinically approved aminoglycosides gentamicin, tobramycin, and amikacin can suppress naturally occurring IDUA premature stop mutations (disease-associated nonsense mutations) in a mammalian translation system, restoring full-length protein. Suppression efficiency is context-dependent, determined primarily by the tetranucleotide termination signal (stop codon plus +1 nucleotide).\",\n      \"method\": \"Readthrough reporter constructs and IDUA cDNA constructs with premature stop mutations in mammalian translation system, enzyme activity assay\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mammalian translation system with both reporter and disease cDNA constructs, single lab\",\n      \"pmids\": [\"12072912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Lentiviral-mediated IDUA gene transfer resulted in IDUA transgene expression highest in liver and spleen; secretion of corrective enzyme from these tissues into plasma allowed cross-correction of distant tissues (kidney, heart, lung) via uptake of secreted enzyme, demonstrating that 1% of normal IDUA activity is sufficient to normalize GAG levels in urine, liver, and spleen of MPS I mice.\",\n      \"method\": \"In vivo lentiviral vector injection (tail vein) in MPS I mice, PCR for integration, enzyme activity assay, GAG quantification in tissues\",\n      \"journal\": \"Human gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse model with enzyme activity, GAG quantification, and PCR localization of vector; single lab\",\n      \"pmids\": [\"15703491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The knock-in Idua-W392X mouse (analogous to human IDUA-W402X) shows no detectable alpha-L-iduronidase activity, increased sulfated GAG excretion in urine and storage in multiple tissues, bone abnormalities, and altered metabolism, establishing this as a faithful model of MPS I-H with complete loss of lysosomal enzyme function.\",\n      \"method\": \"Gene targeting/knock-in, enzyme activity assay, GAG quantification, histology, electron microscopy, X-ray imaging\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (enzyme assay, biochemical GAG measurement, histology, EM) in a genetically defined animal model\",\n      \"pmids\": [\"19751987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The designer aminoglycoside NB84 suppresses the Idua-W392X premature termination codon more efficiently than conventional aminoglycosides (gentamicin, G418, amikacin, paromomycin), restoring sufficient functional alpha-L-iduronidase activity to partially reverse lysosomal GAG accumulation in mouse embryonic fibroblasts and significantly reduce urine and tissue GAG storage in vivo.\",\n      \"method\": \"Suppression assay in mouse embryonic fibroblasts, enzyme activity assay, GAG quantification, in vivo drug administration to Idua-W392X mice\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — both in vitro (MEFs) and in vivo suppression with multiple drug comparisons and functional readouts (enzyme activity + GAG levels)\",\n      \"pmids\": [\"22056610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Murine IDUA fused to the carboxyl terminus of a chimeric anti-transferrin receptor monoclonal antibody (cTfRMAb-IDUA fusion protein) retains comparable enzyme activity (776 ± 79 units/μg protein) to recombinant IDUA, crosses the blood-brain barrier via transferrin receptor-mediated transport, and reverses pre-existing lysosomal inclusion bodies in brain by 73% and reduces GAGs in peripheral tissues of MPS I mice.\",\n      \"method\": \"Fusion protein engineering, enzyme activity assay, intravenous administration to MPS I null mice, GAG quantification, semithin brain section quantitation of lysosomal inclusion bodies\",\n      \"journal\": \"Molecular pharmaceutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzyme activity reconstitution of fusion protein plus in vivo functional correction with quantitative histological and biochemical readouts\",\n      \"pmids\": [\"21667973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A novel IDUA splice site mutation (c.1727+3G>C) causes aberrant splicing of intron 12 (insertion of GTCC), introducing a frameshift and premature termination codon (p.Cys577SerfsX15), with the deleterious effect primarily due to C-terminal truncation. Additionally, exon 4 skipping is a normal alternative splicing event (25–34% of transcripts in healthy individuals), potentially regulating iduronidase activity levels.\",\n      \"method\": \"Sequence analysis of IDUA transcripts, RT-PCR of leukocyte RNA, gene expression studies\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — RT-PCR characterization of aberrant splicing product confirmed mechanistically, single lab\",\n      \"pmids\": [\"21831683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chloramphenicol treatment of MPS I patient fibroblasts (carrying p.W402X/p.W402X) produced a ~100-fold increase in IDUA activity; cDNA sequencing showed only alleles without the nonsense mutation were amplified even after treatment, indicating that nonsense alleles are targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than stop codon readthrough.\",\n      \"method\": \"Cell culture treatment of patient fibroblasts, IDUA enzyme activity assay, cDNA sequencing\",\n      \"journal\": \"Current pharmaceutical biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — enzyme activity assay plus molecular analysis of mRNA from patient cells, single lab\",\n      \"pmids\": [\"23167761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Expression of novel MPS I mutations (including p.V620F, p.W626X) in Chinese hamster ovary (CHO) cells confirmed pathogenicity. Missense mutations localized to the hydrophobic core of IDUA are associated with severe phenotype, while surface-localized missense mutations cause attenuated phenotypes. Mutations in the C-terminal 130 amino acids cause clinical disease, establishing functional importance of the IDUA C-terminus.\",\n      \"method\": \"Transient expression in CHO cells, enzyme activity assay, 3D protein modeling\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based expression assays combined with structural analysis, single lab\",\n      \"pmids\": [\"19396826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Novel p.E276K IDUA missense mutation significantly reduces alpha-L-iduronidase activity when expressed in COS-7 cells by transient transfection, confirming it as a disease-causing variant.\",\n      \"method\": \"Transient transfection of mutant IDUA construct into COS-7 cells, enzyme activity assay\",\n      \"journal\": \"Molecular vision\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct enzyme activity measurement from expressed mutant protein, single lab, single method\",\n      \"pmids\": [\"21364962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The p.X654R (c.*1T>C) IDUA variant produces an mRNA encoding a protein with 38 additional amino acids (C-terminal extension); COS-7 cells expressing this variant show an elevated apparent molecular mass by Western blot and extremely low enzyme activity, while p.W312X and p.Q380X produce no detectable protein by Western blot. This established that p.X654R is a hypomorphic allele with residual activity resulting in intermediate MPS I.\",\n      \"method\": \"Expression in COS-7 cells, enzyme activity assay, Western blot, 3'RACE sequencing of mutant mRNA\",\n      \"journal\": \"Annals of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods (3'RACE, Western blot, enzyme assay) in single lab characterizing molecular consequence\",\n      \"pmids\": [\"29282708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The p.L18P IDUA mutation alters the signal peptide structure (reducing it to 25 amino acids and altering its secondary structure), likely impairing lysosomal targeting of alpha-L-iduronidase, based on bioinformatics analysis of signal peptide properties and clinical correlation with attenuated phenotype featuring bone/cartilage symptoms without visceral or cognitive involvement.\",\n      \"method\": \"Bioinformatics signal peptide analysis, clinical phenotyping\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no direct experimental validation of altered localization\",\n      \"pmids\": [\"25256405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Triazole-iduronic acid hybrid molecules synthesized by click chemistry were identified as the first small molecules that inhibit and thermally stabilize recombinant human alpha-L-iduronidase (rh-α-IDUA) in vitro, suggesting pharmacological chaperone potential.\",\n      \"method\": \"Enzyme inhibition assay, thermal denaturation/stability assay of rh-α-IDUA with library compounds\",\n      \"journal\": \"Chemical communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro enzyme and thermal stability assays, single lab, novel compound class identified\",\n      \"pmids\": [\"29473068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A functional HEK293-based expression platform combining fluorescence-based alpha-iduronidase activity assay and semi-quantitative Western blotting determined that pseudodeficiency IDUA variants (p.His82Gln, p.Ala79Thr, p.Val322Glu, p.Asp223Asn) variably reduce but do not abolish specific activity, while pathogenic variants (p.Ser633Leu, p.His240Arg) show very low activity. p.His240Arg showed 5-fold higher specific activity than p.Ser633Leu despite both causing Scheie syndrome, and p.Ser586Phe and p.Ile272Leu VUS variants had specific activities in the pseudodeficiency range.\",\n      \"method\": \"Viral delivery of IDUA variants into IDUA-deficient HAP1 cells, single-cell cloning, enzyme activity assay, Western blot for protein quantification\",\n      \"journal\": \"International journal of neonatal screening\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct enzyme specific activity measurement from isogenic expression system with multiple variants, single lab\",\n      \"pmids\": [\"33198351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Reduction of D-idua (Drosophila IDUA ortholog) by RNAi causes lethality at the pupal stage, increased lysosome number and size in brain and muscle, impaired lysosome acidification leading to dysfunctional lysosome-autophagosome fusion and autophagy flux blockade, and a metabolic shift toward glycolysis and lipogenesis. Starvation rescued both autophagy/lysosome phenotypes and metabolic alterations, establishing that IDUA deficiency causes secondary autophagy impairment and metabolic dysregulation.\",\n      \"method\": \"RNAi-mediated knockdown in Drosophila, lysosome staining and imaging, autophagy flux assay, metabolic pathway analysis, starvation rescue experiment\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vivo readouts (lethality, lysosome morphology, autophagy, metabolism) in Drosophila model with rescue experiment\",\n      \"pmids\": [\"35011691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Injection of mutated z-idua-L346R mRNA into zebrafish embryos reduced z-Idua enzymatic activity and caused dominant negative defective phenotypes (compared to wild-type injected), while z-idua-E540-frameshift mRNA provided partial enzymatic activity and did not cause defective phenotypes, establishing that enzymatic activity of IDUA directly correlates with disease phenotype in this model system.\",\n      \"method\": \"Zebrafish morpholino knockdown, mRNA microinjection of mutant idua, z-Idua enzymatic activity assay, phenotypic scoring\",\n      \"journal\": \"Journal of personalized medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo zebrafish model with enzymatic activity measurement and phenotypic readout, single lab\",\n      \"pmids\": [\"35893292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IDUA morpholino knockdown in zebrafish larvae upregulates TP53 signaling and LC3/GABARAP family protein-mediated autophagy, and upregulates leukotriene A4 hydrolase-mediated arachidonic acid metabolism; introduction of wild-type human IDUA mRNA rescued developmental defects and aberrant signaling, placing IDUA upstream of these pathways.\",\n      \"method\": \"Zebrafish IDUA morpholino knockdown, transcriptome profiling, rescue with wild-type IDUA mRNA, IDUA enzyme activity assay\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomic pathway analysis with mRNA rescue validation in vivo, single lab\",\n      \"pmids\": [\"37347427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Heterozygous loss-of-function mutations in IDUA have a gene-dosage effect on Aβ40 levels in brain interstitial fluid in C57BL/6 mice and significantly increase Aβ plaque formation in the 5xFAD Alzheimer's disease mouse model, establishing that partial IDUA deficiency is sufficient to perturb amyloid processing.\",\n      \"method\": \"In vivo mouse genetics (IDUA heterozygous knock-out crossed with 5xFAD), brain interstitial fluid Aβ40 measurement, amyloid plaque quantification\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo mouse genetic model with direct biochemical readout, single preprint study not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Characterization of over 30 IDUA variants using HEK293 expression platform revealed that different variants have distinct effects on enzyme folding, processing, and stability (not just catalytic activity), and that relative specific activity serves as a first-level functional classifier. Some variants reduce activity primarily through folding/stability defects rather than direct catalytic impairment.\",\n      \"method\": \"HEK293-based expression of IDUA variants, fluorescence enzyme activity assay, semi-quantitative Western blotting for protein folding/processing assessment\",\n      \"journal\": \"NPJ genomic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct enzyme activity plus protein quantification across >30 variants, single lab with orthogonal methods\",\n      \"pmids\": [\"39702574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The novel IDUA splice variant c.159-9T>A causes two aberrant splicing events—exon 2 skipping and intron 1 retention—as demonstrated by minigene splicing assay, establishing the molecular consequence of this mutation on IDUA mRNA processing.\",\n      \"method\": \"Minigene splicing assay, WES, SNP array, Sanger sequencing\",\n      \"journal\": \"Molecular genetics & genomic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct minigene functional assay demonstrating aberrant splicing, single lab\",\n      \"pmids\": [\"39132856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The novel IDUA deletion p.His356_Gln362del disrupts the protein's substrate-binding site, causing structural deformation and complete loss of enzymatic activity; the missense mutation p.Pro533Arg affects protein stability and flexibility by introducing a bulkier arginine residue that interferes with the contact region between the β-sheet structure and substrate-bound helix, reducing substrate affinity.\",\n      \"method\": \"Sanger sequencing, SWISS-MODEL structural homology modeling, DynaMut stability prediction, clinical phenotyping\",\n      \"journal\": \"Molecular genetics and metabolism reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — structural analysis primarily computational, no direct enzyme activity measurement reported for the novel deletion variant\",\n      \"pmids\": [\"40291162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Combining two or more clinically benign IDUA variants in cis on a single allele reduces the specific activity of the resulting enzyme into the pathogenic range (comparable to attenuated or severe MPS I-associated variants), as measured by the established HAP1-cell functional platform.\",\n      \"method\": \"Viral delivery of single and combined IDUA variant constructs into IDUA-deficient HAP1 cells, single-cell cloning, enzyme specific activity assay, Western blot\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct enzyme specific activity measurement from isogenic expression system, single lab\",\n      \"pmids\": [\"40359731\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IDUA encodes alpha-L-iduronidase, a lysosomal hydrolase that degrades glycosaminoglycans heparan sulfate and dermatan sulfate; the enzyme is translated with a signal peptide directing it to lysosomes, requires correct folding and C-terminal integrity for activity, and loss-of-function mutations spanning missense, nonsense, frameshift, and splice-site classes all cause MPS I by abolishing or severely reducing enzymatic activity, which blocks lysosomal GAG catabolism and secondarily impairs autophagy flux, activates TP53 and autophagy signaling pathways, and—at the heterozygous level—modulates amyloid β processing in mouse models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IDUA encodes alpha-L-iduronidase, a lysosomal hydrolase that degrades the glycosaminoglycans heparan sulfate and dermatan sulfate, and loss of its activity causes the lysosomal storage disorder mucopolysaccharidosis type I (MPS I) [#0, #7]. The enzyme is translated with a signal peptide that directs it to the lysosome, and a mutation reducing and restructuring this signal peptide is associated with an attenuated, predominantly skeletal phenotype [#15]. The IDUA locus has a housekeeping-gene architecture (GC-rich, Sp1-bound promoter lacking TATA/CAAT motifs) [#1]. Disease-causing lesions span the full allelic spectrum — missense, nonsense, frameshift, and splice-site mutations — and act through distinct molecular routes: destabilizing the folded protein, disrupting the substrate-binding site, abolishing protein production, or generating aberrantly spliced transcripts with intron retention, exon skipping, or premature termination codons [#2, #3, #12, #14, #23]. Catalytic activity correlates directly with clinical severity; missense changes in the hydrophobic core and the C-terminal ~130 residues are severe, surface changes are attenuated, and folding/stability defects rather than direct catalytic impairment underlie many hypomorphic alleles [#12, #22]. Enzyme specific activity provides a quantitative functional classifier that separates pathogenic, pseudodeficiency, and benign variants, and combinations of individually benign variants in cis can drop activity into the pathogenic range [#17, #25]. Loss of IDUA blocks lysosomal GAG catabolism and secondarily impairs lysosomal acidification and autophagosome-lysosome fusion, blocking autophagy flux and shifting metabolism toward glycolysis and lipogenesis [#18]; in vivo it acts upstream of TP53 and LC3/GABARAP-mediated autophagy signaling [#20]. Because secreted enzyme can be taken up by distant tissues, as little as 1% of normal activity normalizes GAG storage, a principle that underlies enzyme-replacement, gene-transfer, and nonsense-suppression therapeutic strategies [#6, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Establishing that IDUA encodes the lysosomal hydrolase degrading heparan and dermatan sulfate and mapping it to 4p16.3 anchored the gene to its enzymatic function and chromosomal location.\",\n      \"evidence\": \"In situ hybridization and Southern blot of human-mouse hybrids with enzyme activity assay\",\n      \"pmids\": [\"2220820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define gene structure or catalytic mechanism\", \"No mutation-to-phenotype correlation yet\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Cloning the orthologous canine gene revealed a 14-exon housekeeping-gene architecture and showed a splice-donor mutation causes intron retention and premature termination, framing how splice lesions disrupt IDUA.\",\n      \"evidence\": \"Gene cloning, RT-PCR, primer extension and genomic sequencing in canine MPS I\",\n      \"pmids\": [\"1339393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human gene structure inferred by analogy\", \"Did not address protein folding or substrate binding\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Expression of mutagenized human cDNAs established that individual IDUA mutations produce distinct molecular consequences — trace activity, residual activity, low mRNA, exon skipping, cryptic splicing — explaining phenotypic variability from mild Scheie to severe disease.\",\n      \"evidence\": \"Transfection of mutant cDNAs into COS cells, enzyme assays, RT-PCR splice analysis; chemical-cleavage mutation detection\",\n      \"pmids\": [\"8328452\", \"8213840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited number of variants\", \"No structural basis for activity loss\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Polymorphic residues were shown to modulate enzyme specific activity, indicating sequence context tunes IDUA output beyond simple loss-of-function.\",\n      \"evidence\": \"Site-directed mutagenesis and expression in COS-7 cells with activity assays\",\n      \"pmids\": [\"9536518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study\", \"Physiological relevance of activity gains unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that clinical aminoglycosides suppress IDUA nonsense mutations to restore full-length protein opened nonsense-readthrough as a therapeutic avenue and identified the termination context as the key determinant.\",\n      \"evidence\": \"Readthrough reporter and IDUA premature-stop cDNA constructs in a mammalian translation system\",\n      \"pmids\": [\"12072912\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only\", \"Suppression efficiency low and context-dependent\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Lentiviral gene transfer in MPS I mice showed secreted enzyme cross-corrects distant tissues and that 1% of normal activity suffices to normalize GAG, defining the therapeutic threshold and metabolic cross-correction principle.\",\n      \"evidence\": \"In vivo lentiviral delivery in MPS I mice with vector PCR, enzyme assay, tissue GAG quantification\",\n      \"pmids\": [\"15703491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CNS correction not addressed\", \"Durability and integration safety not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Combining expression assays with structural modeling established that core-localized missense mutations are severe while surface mutations are attenuated, and that the C-terminal ~130 residues are functionally essential.\",\n      \"evidence\": \"Transient CHO expression with enzyme assays and 3D protein modeling of MPS I variants\",\n      \"pmids\": [\"19396826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modeling-based structural inference\", \"Folding versus catalytic contributions not separated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The Idua-W392X knock-in mouse provided a faithful null model recapitulating MPS I-H biochemistry and pathology, enabling mechanistic and preclinical work.\",\n      \"evidence\": \"Gene-targeted knock-in with enzyme assay, GAG quantification, histology, EM, and X-ray imaging\",\n      \"pmids\": [\"19751987\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Models a single nonsense allele\", \"Secondary cellular pathways not dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Designer aminoglycoside NB84 and a blood-brain-barrier-penetrant antibody-IDUA fusion demonstrated that both stop-codon suppression and receptor-mediated brain delivery can restore activity and reverse storage in vivo, including in the CNS.\",\n      \"evidence\": \"Suppression assays in MEFs and Idua-W392X mice; cTfRMAb-IDUA fusion enzyme activity and intravenous correction with brain inclusion-body quantitation\",\n      \"pmids\": [\"22056610\", \"21667973\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term efficacy and toxicity unaddressed\", \"Limited to specific alleles/delivery systems\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterization of novel missense and splice variants (p.E276K; c.1727+3G>C) confirmed pathogenicity and showed C-terminal truncation is the deleterious driver, while documenting exon 4 skipping as a normal regulatory splicing event.\",\n      \"evidence\": \"COS-7 transient expression with enzyme assays; RT-PCR transcript analysis of leukocyte RNA\",\n      \"pmids\": [\"21364962\", \"21831683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Function of physiological exon-4 skipping unproven\", \"Single-variant resolution\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Chloramphenicol's ~100-fold activity increase in W402X patient fibroblasts, with no detectable nonsense allele transcript, revealed that nonsense alleles undergo nonsense-mediated decay and that some drugs act independently of readthrough.\",\n      \"evidence\": \"Patient fibroblast drug treatment, enzyme assay, and cDNA sequencing\",\n      \"pmids\": [\"23167761\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of chloramphenicol action undefined\", \"Single cell line/genotype\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The C-terminally extended p.X654R allele was shown to produce an enlarged, near-inactive protein causing intermediate MPS I, while nonsense variants yielded no detectable protein, refining genotype-phenotype rules for hypomorphic alleles.\",\n      \"evidence\": \"COS-7 expression, enzyme assay, Western blot, and 3'RACE of mutant mRNA\",\n      \"pmids\": [\"29282708\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of activity loss from C-terminal extension not detailed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"An isogenic HAP1/HEK293 expression platform quantitatively distinguished pseudodeficiency, pathogenic, and VUS variants by specific activity, providing a functional framework for newborn-screening interpretation.\",\n      \"evidence\": \"Viral delivery of variants into IDUA-deficient HAP1 cells, single-cell cloning, fluorescence activity assay, Western blot\",\n      \"pmids\": [\"33198351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Recombinant expression may not capture tissue context\", \"Single-lab platform\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Drosophila IDUA knockdown linked enzyme loss to impaired lysosome acidification, blocked autophagosome-lysosome fusion, and a glycolytic/lipogenic metabolic shift, all reversible by starvation, establishing secondary autophagy and metabolic dysregulation downstream of IDUA deficiency.\",\n      \"evidence\": \"RNAi knockdown in Drosophila with lysosome imaging, autophagy flux assays, metabolic analysis, and starvation rescue\",\n      \"pmids\": [\"35011691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog model\", \"Direct relevance of metabolic shift to human MPS I unconfirmed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Zebrafish mRNA injection showed enzymatic activity correlates directly with phenotype, with a dominant-negative allele (z-idua-L346R) and a residual-activity frameshift allele behaving differently, reinforcing activity as the disease determinant.\",\n      \"evidence\": \"Zebrafish morpholino knockdown and mutant mRNA microinjection with enzyme assays and phenotypic scoring\",\n      \"pmids\": [\"35893292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative mechanism not molecularly defined\", \"Ortholog model\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Zebrafish knockdown and human IDUA mRNA rescue placed IDUA upstream of TP53 signaling, LC3/GABARAP autophagy, and leukotriene A4 hydrolase-mediated arachidonic acid metabolism, connecting enzyme loss to defined signaling cascades.\",\n      \"evidence\": \"Zebrafish IDUA morpholino knockdown, transcriptome profiling, and wild-type mRNA rescue\",\n      \"pmids\": [\"37347427\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic links between GAG storage and TP53/autophagy unproven\", \"Transcriptome correlations not validated at protein level\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Systematic characterization of over 30 variants showed many act through folding, processing, and stability defects rather than direct catalytic loss, establishing relative specific activity as a first-level functional classifier.\",\n      \"evidence\": \"HEK293 expression of >30 variants with fluorescence activity assay and semi-quantitative Western blotting\",\n      \"pmids\": [\"39702574\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Folding defects inferred from protein abundance, not direct biophysics\", \"Single-lab platform\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Heterozygous IDUA loss-of-function exerted a gene-dosage effect on brain Abeta40 and increased plaque burden in the 5xFAD model, implicating partial IDUA deficiency in amyloid processing beyond classic MPS I.\",\n      \"evidence\": \"Mouse genetics (IDUA heterozygous knockout crossed with 5xFAD), interstitial fluid Abeta40 measurement, plaque quantification (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Mechanism linking IDUA to amyloid metabolism unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that combinations of individually benign IDUA variants in cis lower activity into the pathogenic range showed complex-allele additivity as a genotype mechanism in MPS I.\",\n      \"evidence\": \"Viral delivery of single and combined variant constructs in HAP1 cells with specific activity assay and Western blot\",\n      \"pmids\": [\"40359731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Recombinant system; clinical cases of such complex alleles not confirmed\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GAG storage mechanistically triggers TP53 activation, autophagy blockade, metabolic reprogramming, and altered amyloid processing — and whether these secondary pathways are therapeutic targets in human MPS I — remains unresolved.\",\n      \"evidence\": \"Open question synthesized across ortholog and mouse studies\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct mechanistic link from GAG accumulation to TP53/autophagy in human cells\", \"Amyloid finding is a single preprint\", \"No structural model defining catalytic versus stability determinants experimentally validated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 7, 17, 22]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 7, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:8953854\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [18, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":8,"faith_total":8,"faith_pct":100.0}}